SYK Q2 2026 Earnings Analysis
Stryker posted 9% organic growth, $3.69 adjusted EPS (+17.9%), and narrowed FY guidance to 8.3%-9.3% sales and $14.95-$15.10 EPS, driven by capital recovery and record Mako installations.
Key Metrics
Puntos clave
- 9% Q2 growth from capital equipment demand; elevated backlog supports 8.3%-9.3% FY guidance.
- Mako platform delivered best-ever Q2 installations; RPS launched full commercial availability.
- Adjusted EPS up 17.9% to $3.69 from gross margin gains and operational efficiency.
Audio not available for this episode.
Transcript is available below.
Escuchar en
Disponible en
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Stryker's Q2 2026 results — and this is a good one, because it's really a comeback story. But first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Okay, so context matters a lot here. Stryker got hit by a cybersecurity incident that knocked out manufacturing for about a month in Q1. So Q2 is really the "how fast can they recover" quarter.
And the answer is — pretty fast. Organic sales growth of 9%, adjusted EPS of $3.69, up almost 18% year over year. For a $25 billion company that had plants offline for weeks, that's a strong number.
Right, CEO Kevin Lobo actually said it himself on the call — growing around 9% "given that we were knocked out for almost an entire month" is a pretty good outcome. And you saw strength pretty much everywhere: MedSurg and Neurotechnology up over 9%, Orthopedics up 8.6%. U.S. trauma and extremities grew over 12%, medical devices — Sage, Emergency Care — grew north of 13%.
The one soft spot was peripheral vascular, down almost 7% in the U.S. There was a supply disruption at one of their Inari manufacturing plants that caused a real backorder problem. They actually had to ration product to their best customers.
Which is a rough thing to say out loud on an earnings call, but at least it's honest. Management expects that backorder to work itself down to manageable levels by the end of Q3, and they're still bullish long-term on that business — especially with the AVS acquisition that just closed, which adds an IVL, intravascular lithotripsy, product to the portfolio.
Let's talk strategy for a second, because there were some real headline moments here. Mako, their robotics platform, just turned 20 years old, and they had their best-ever second quarter for Mako installations, both in the U.S. and internationally. Over 2.5 million procedures done globally now, systems in 47 countries.
And the bigger story is the full commercial launch of Mako RPS — that's their handheld robotics system. It's aimed at surgeons who aren't ready to commit to a full Mako cart, especially in ambulatory surgery centers doing total knees. Lobo said the haptic feedback is what's really wowing surgeons — that you can get that kind of precision in a handheld device.
They're also rolling out Triathlon Gold, a new insert for their knee system, a new total ankle replacement called Encompass, and a trauma plating system called Pangaea that's launching in Europe. So despite the manufacturing hit, the product pipeline didn't really slow down.
Now, the money question everyone on the call kept circling back to — capital equipment. Stryker's sitting on an elevated order backlog because demand outpaced their ability to produce during the recovery. Beds, in particular — their ProCuity hospital bed business — has huge order volume they just haven't been able to fill yet.
And management's plan is straightforward: add manufacturing shifts and grind through the backlog in the second half of the year. Lobo was pretty confident about this, saying these aren't new products, this is stuff they know how to make — it's purely an execution and capacity question, not a demand question.
That came up a lot in the Q&A, actually — analysts pushing hard on whether Stryker can really hit an implied 11% organic growth rate in the back half to reach their guidance midpoint. Lobo's response was basically, "we raised the low end of our guidance from 8% to 8.3%, that alone should tell you how confident we are."
On guidance — they narrowed the full-year range. Organic sales growth now expected at 8.3% to 9.3%, and adjusted EPS between $14.95 and $15.10. Interesting wrinkle: even though they beat EPS this quarter, guidance for the full year didn't move up as much as some expected.
CFO Preston Wells explained that one pretty clearly — some of the Q2 EPS beat came from tariff refunds, but that's being offset by ongoing cybersecurity remediation costs and lost manufacturing absorption. So it nets out over the full year rather than flowing straight through.
One more thing worth flagging for investors — capital allocation. Stryker's got about $3.5 billion in cash and marketable securities, and they announced they're resuming share buybacks this quarter for the first time in about six years, alongside continued M&A.
That's notable. Vijay Kumar from Evercore asked about this directly, and Preston Wells said M&A is still priority number one, but given how much cash flow they're generating now versus six years ago, they can do both — buybacks and dealmaking — without giving up firepower. There's already a billion dollars in prior board authorization they can tap.
So, bottom line for listeners — Stryker took a real hit from a cyber incident earlier this year, and Q2 shows a business that's clawing its way back with strong underlying demand across almost every product line. The vascular business is the one lingering soft spot, but even there, management sounds confident it's a temporary supply issue, not a demand or competitive problem.
And the back half of the year is really a story about execution — can they ramp manufacturing fast enough to convert that backlog into revenue. Management's tone was confident, not defensive, which is usually a decent signal, but it's something to watch when Q3 results come out in October. Before we wrap — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
We'll be back next quarter to see how that production ramp actually played out. Thanks for listening to Beta Finch — see you next time.